Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 10 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Kite Pharma Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area, currently facing 13 pending office actions. These actions are distributed across a matching number of distinct examiners, showing a 1-to-1 ratio between pending actions and the examining staff involved. This distribution suggests that no single examiner holds a disproportionate influence over the company's current prosecution pipeline.
The workload spans 10 distinct art units, reflecting a diverse range of technical subject matter within the Biotechnology & Pharmaceuticals sector. SANGHERA, STEVEN G.S. is identified as the busiest examiner, though this individual is responsible for only 1 pending office action. This indicates that the workload is spread evenly across the examining staff, rather than being clustered under a few specific individuals.
For practitioners, the involvement of 10 distinct art units suggests that prosecution strategies must be tailored to the specific standards of multiple specialized groups. With 13 distinct examiners, the portfolio lacks the examiner-specific concentration often seen in smaller portfolios, requiring a broad approach to managing examiner interactions.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (46%) |
| §103 only | 3 (23%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| Multi-statute (no §101) | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANGHERA, STEVEN G.S. | 1 | 30.8% | +30.4% |
| POHNERT, STEVEN C | 1 | 12.4% | +18.5% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
| FISHER, BRITTANY I | 1 | 84.5% | +12.3% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038888 | CULTURE VESSEL FOR A BIOPROCESSING SYSTEM | FISHER, BRITTANY I | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | SANGHERA, STEVEN G.S. | 25d overdue |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | NGUYEN, QUANG | 18d overdue |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | FRITCHMAN, REBECCA M | 8d overdue |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | DAUNER, JOSEPH G | 13d |
| 18604854 | IMPACT OF TUMOR MICROENVIRONMENT ON EFFICACY OF IMMUNOTHERAPY | POHNERT, STEVEN C | — |
| 18292254 | DNVSIG3 AND DNVSIG8 RECEPTORS AND METHODS OF USING THE SAME | LEE, YIE CHIA | — |
| 17853708 | METHOD FOR IDENTIFYING VARIANTS IN GENE PRODUCTS FROM GENE CONSTRUCTS USED IN CELL THERAPY APPLICATIONS | LU, FRANK WEI MIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | SANGHERA, STEVEN G.S. | 25d overdue |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | NGUYEN, QUANG | 18d overdue |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | FRITCHMAN, REBECCA M | 8d overdue |
| 18175049 | ALLOGENEIC THERAPEUTIC CELLS | SHUPE, ELIZABETH A | 4d overdue |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | DAUNER, JOSEPH G | 13d |
| 18604854 | IMPACT OF TUMOR MICROENVIRONMENT ON EFFICACY OF IMMUNOTHERAPY | POHNERT, STEVEN C | — |
| 18292254 | DNVSIG3 AND DNVSIG8 RECEPTORS AND METHODS OF USING THE SAME | LEE, YIE CHIA | — |
| 18495531 | EFFICACY AND DURABLE RESPONSE OF IMMUNOTHERAPY | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 3684 | 1 |
| 1682 | 1 |
| 1674 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| 1796 | 1 |
| 1758 | 1 |
| 1600 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | SANGHERA, STEVEN G.S. | 3684 | §101§103§112 | Final Rejection | 25d overdue | Pending | Feb 03, 2025 |
| 18604854 | IMPACT OF TUMOR MICROENVIRONMENT ON EFFICACY OF IMMUNOTHERAPY | POHNERT, STEVEN C | — | §101§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18292254 | DNVSIG3 AND DNVSIG8 RECEPTORS AND METHODS OF USING THE SAME | LEE, YIE CHIA | — | §101§102§103§112 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | DAUNER, JOSEPH G | 1682 | §101§102§103§112 | Final Rejection | 13d | Pending | Oct 27, 2023 |
| 18495531 | EFFICACY AND DURABLE RESPONSE OF IMMUNOTHERAPY | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18377685 | LARGE SCALE CAR-T IMMUNE CELL MANUFACTURING METHOD UTILIZING LENTIVIRAL VECTOR TRANSFECTION | GU, QINHUA | 1633 | §103 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | NGUYEN, QUANG | 1631 | §102§103§112 | Non-Final OA | 18d overdue | Pending | Jun 01, 2023 |
| 18038888 | CULTURE VESSEL FOR A BIOPROCESSING SYSTEM | FISHER, BRITTANY I | 1796 | §103 | Final Rejection | — | Pending | May 25, 2023 |
| 18175049 | ALLOGENEIC THERAPEUTIC CELLS | SHUPE, ELIZABETH A | 1643 | §103DP | Final Rejection | 4d overdue | Pending | Feb 27, 2023 |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Final Rejection | 8d overdue | Pending | Jul 29, 2022 |
| 17814811 | SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | FAUST, AMBER KATHLEEN | 1643 | §103DP | Final Rejection | 23d overdue | Pending | Jul 25, 2022 |
| 17853708 | METHOD FOR IDENTIFYING VARIANTS IN GENE PRODUCTS FROM GENE CONSTRUCTS USED IN CELL THERAPY APPLICATIONS | LU, FRANK WEI MIN | 1600 | §101§112 | Non-Final OA | — | Pending | Jun 29, 2022 |
| 17675294 | IMMUNOTHERAPIES | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | — | Pending | Feb 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial